Sana Biotechnology IPO
Sana Biotechnology is a cell and gene therapy company focused on developing engineered cells as medicines for patients. The company's platform approach to cell engineering and its focus on treating cancer, diabetes, and other diseases has attracted significant investor attention in the biotech space.
Key Facts
| Industry | Cell and Gene Therapy |
| Founded | 2018 |
| Headquarters | Seattle, WA |
| Employees | ~400 |
| Website | sana.com |
| Funding | IPO in February 2021 at $20 per share. Total raised: ~$676M including IPO proceeds |
About Sana Biotechnology
Sana Biotechnology is developing engineered cell and gene therapies designed to control and repair genes, replace missing or damaged cells, and reprogram cells in vivo. The company's platform combines several cutting-edge technologies including hypoimmune cells designed to evade immune rejection, complementary gene regulation systems, and targeted lipid nanoparticles for in vivo delivery. Sana's approach aims to create off-the-shelf allogeneic cell therapies that could overcome current limitations in personalized cell therapy manufacturing and immune compatibility. The company has built a comprehensive pipeline targeting cancer, diabetes, central nervous system disorders, and other diseases, with lead programs focusing on hypoimmune CAR-T cells and beta cell replacement therapies for diabetes.
IPO Status
Sana Biotechnology went public in February 2021 through a traditional IPO, raising approximately $676 million at a valuation of about $2.6 billion. The company trades on NASDAQ under the ticker symbol 'SANA'. The IPO was well-received initially, but like many biotech stocks, Sana's share price has experienced volatility as the company advances its clinical pipeline. The company continues to develop its cell engineering platform and advance multiple programs through clinical trials, though it remains in the pre-revenue stage typical of clinical-stage biotechnology companies.
Competitors
Frequently Asked Questions
Does Sana Biotechnology have a stock?
Yes, Sana Biotechnology completed its IPO in February 2021, raising approximately $676 million. The cell and gene therapy company trades publicly on NASDAQ under ticker 'SANA'.
When is the Sana Biotechnology IPO date?
Sana Biotechnology already went public in February 2021, so there is no upcoming IPO. The company completed a traditional initial public offering and began trading on NASDAQ.
How can I buy Sana Biotechnology stock?
You can buy Sana Biotechnology stock through any brokerage platform since it trades on NASDAQ under ticker 'SANA'. The stock is available for purchase during regular trading hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts